Roche receives FDA clearance for new Troponin T test to detect patients with suspected heart attack

Roche announced that it has received the 510(k) clearance for its Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for patients with a suspected heart attack. With this clearance, Roche is the first IVD company in the U.S. to provide the next generation Troponin testing for patients as an aid in the diagnosis of myocardial infarction, enabling clinicians to more accurately identify patients experiencing a heart attack.

Every minute counts Every 43 seconds someone in the U. S. has a heart attack, or acute myocardial infarction (AMI), which occurs when the blood supply to an area of the heart is interrupted. The longer time the heart is without proper blood supply, the greater the damage. Troponin, a specific marker of cardiac cell death, is released into the blood stream when cardiac cells are being damaged.

Patients with chest pain and other symptoms suggestive of AMI account for approximately 8 million of all emergency room consultations in the U.S., but only a fraction of them (5-20%) are actually having an AMI. Hence, fast and accurate diagnosis of AMI requires sensitive diagnostic tests that can detect early troponin release, allowing healthcare providers to make confident clinical decisions for their patients and appropriately manage hospital resources. In a heart attack, early diagnosis and initiation of treatment can reduce the amount of cardiac cell death thus potentially saving and improving quality of lives. This next generation Troponin T test from Roche is able to provide accuracy at lower levels of troponin to aid in correctly identifying patients having an AMI.

Moreover, this next generation of TnT test from Roche has been available in the rest of the world for the past seven years during which time it has been rapidly adopted by clinicians and its clinical diagnostic utility is supported by more than 600 peer-reviewed publications.

"As an emergency doctor whose job is to make decisions on patients with chest pain, my ability to do this safely and accurately is driven by the sensitivity of the troponin assay. FDA clearance of this new Roche TnT assay is easily the best news in the last decade for emergency medicine patients presenting with chest pain."

The Elecsys TnT Gen 5 test from Roche enables better decisions

The Elecsys® Troponin T Gen 5 STAT test from Roche detects cardiac troponin which is the preferred biomarker for the diagnosis of heart attack in clinical practice. In combination with an electrocardiogram (ECG) and signs of ischemia, troponin has become the gold standard as an aid in the diagnosis of heart attack. The higher sensitivity of the Roche TnT Gen 5 STAT assay in conjunction with the rapid turnaround time of nine minutes can significantly accelerate decision-making, and allows the detection of smaller infarctions thereby maximizing the potential for effective treatment.

With such compelling clinical utilities and the automation advantages associated with Roche solutions, the Elecsys TnT Gen 5 STAT test can provide the confidence that healthcare professionals need to diagnose and manage patients in emergency settings and beyond.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Heart healthy adults have lower lifetime risk of type 2 diabetes